Replies to post #189787 on Biotech Values

[dewophile]

I didn't read most of the NASH abstracts - if you have time feel free to post any you think are worthwhile
I did skim through a preclinical abstract on a new FXR agonist in an animal model and i recall enta saying they had more preclinical data than what they have shared thus far so i expect them to present something comparable at an upcoming meeting (unless they get bought out first ;)